ASCO26: David Reardon, MD, Glioblastoma Vaccine - Takeaways - MDSpire

ASCO26: David Reardon, MD, Glioblastoma Vaccine

Dana-Farber Cancer Institute's Dr. David Reardon reports on data showing a phase 1 trial looking at a personalized vaccine plus pembrolizumab sparked tumor-targeting T cells in glioblastoma and was linked to longer survival in immune responders.

  • July 1, 2026

Share

  • 1

    Dr. David Reardon presented data from a phase 1 trial on a personalized vaccine for glioblastoma.

  • 2

    The trial combined the personalized vaccine with pembrolizumab.

  • 3

    Results indicated that the treatment stimulated tumor-targeting T cells.

  • 4

    Immune responders in the trial experienced longer survival.

  • 5

    The findings were reported at the ASCO26 conference.

Original Source(s)

ASCO26: David Reardon, MD, Glioblastoma Vaccine

  • July 1, 2026

Related Content

First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial

MCT4 drives HCC progression by activating MMPs and polarizing M2 macrophages

ASCO26: Jennifer Ligibel, MD, BWEL

Dana-Farber Cancer Institute's Dr. Jennifer Ligibel shared updated results from the BWEL study showing a weight loss intervention led to significantly better physical function, global physical and mental health, and symptom in patients with early breast cancer.

  • July 1, 2026

  • 1 min